Trials / Recruiting
RecruitingNCT06927024
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
A Randomized, Sham-controlled Pilot Trial of a Novel Therapeutic Strategy (taVNS) for Autonomic Nervous System (ANS) Dysfunction in Chronic Kidney Disease (CKD)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Active taVNS | Active taVNS delivered via the TENS Device 7000. |
| DEVICE | Sham taVNS | Sham taVNS delivered via the TENS Device 7000. |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2029-01-31
- Completion
- 2029-01-31
- First posted
- 2025-04-15
- Last updated
- 2025-12-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06927024. Inclusion in this directory is not an endorsement.